Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer | Canada Hyperbarics Skip to main content
Study Complement Med Res 2020

Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer

Iyikesici M — Complement Med Res, 2020

View Original on PubMed PMID 31527373
Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers retrospectively analyzed 25 patients with stage IV metastatic pancreatic cancer treated at a Turkish center with a combined protocol of metabolically supported chemotherapy, ketogenic diet, hyperthermia, and HBOT.

What They Found

Median overall survival was 15.8 months and median progression-free survival was 12.9 months -- notably better than historical benchmarks of roughly 11 months for standard chemotherapy alone for this stage. No patient characteristics independently predicted survival.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This was a small retrospective study of 25 patients with no control arm; multiple interventions were combined, making it impossible to determine the specific contribution of HBOT.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Study
Category Uncategorised
Source Pubmed
PubMed ID 31527373
Year Published 2020
Journal Complement Med Res
MeSH Terms Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Diet, Ketogenic; Female; Fluorouracil; Humans; Hyperbaric Oxygenation; Hyperthermia, Induced; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survivors; Gemcitabine

Cite This Study

Share

Related Research

Diving Hyperb Med | 2017 Clinical Guideline

Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment.

Mathieu D, Marroni A, Kot J.
J Int Med Res | 2004 RCT

Effectiveness of hyperbaric oxygen therapy in the treatment of complex regional pain syndrome

Kiralp MZ, Yildiz S, Vural D, et al.
Inflamm Bowel Dis | 2022 Meta-Analysis ★

The effectiveness and safety of hyperbaric oxygen therapy in various phenotypes of inflammatory bowel disease: systematic review with meta-analysis

McCurdy J, Bhatt J, Engel-Yeger B, et al.
Undersea Hyperb Med | 2013 Clinical Study

The efficacy of hyperbaric oxygen therapy in the management of chronic fatigue syndrome

Akarsu S, Tekin L, Ay H, et al.
Am J Physiol Heart Circ Physiol | 2006 Clinical Study

Stem cell mobilization by hyperbaric oxygen

Thom SR, Bhopale VM, Velazquez OC, et al.
See all Uncategorised research
View on PubMed Back to Research Library

Find a Canadian Clinic Treating Uncategorised

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: March 19, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology